Komori
Ono Pharmaceutical (4528) · RiskFirst stated

Risk of failing to establish in-house sales operations in the US and Europe

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of failure of the medium-term management plan and business strategyA theme 33 companies write about · 33 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 9 of 10 companies on the "Worse" side.

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 33 companies compared. The sentences above are computed from all 33.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「In conducting global business activities, we are addressing development risk by expanding the development pipeline to maintain multiple product candidates for launch, gathering information on legal and regulatory requirements, economic conditions, political instability, region-specific natural disasters and uncertainties in the business environment in each country, and considering necessary responses. However, if these risks cannot be completely avoided, the Group’s operating results and financial position may be affected.」

    While advancing the establishment of in-house sales operations in the US and Europe as a strategy, the risk of failure was explicitly identified for the first time as a major strategic risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.